GlassScriptPhysician profile
Ana Mrkaic
NPI 1568854651
$6,574.89
in general payments reported to CMS, 2019-2025
33 companies · $655 in 2025
The $655 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2021: $445 · 2022: $855 · 2023: $1,934 · 2024: $2,467 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,056.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $763.77 | 2021-2024 | Freestyle Libre 3 |
| Regeneron Healthcare Solutions, INC. | $450.85 | 2022-2024 | Libtayo |
| Corcept Therapeutics | $422.93 | 2022-2024 | Korlym |
| Gilead Sciences, INC. | $420.31 | 2021-2023 | Epclusa, Veklury |
| Astrazeneca Pharmaceuticals LP | $390.12 | 2021-2023 | Saphnelo |
| Incyte Corporation | $356.28 | 2022-2024 | Opzelura |
| Ucb, INC. | $354.84 | 2023-2025 | |
| Chiesi USA, INC. | $353.34 | 2024-2025 | Myalept, Mycapssa |
| Novo Nordisk INC | $312.62 | 2022-2023 | Rybelsus, Ozempic |
| Horizon Therapeutics Plc | $274.21 | 2022-2023 | Tepezza |
| E.R. Squibb & Sons, L.L.C. | $267.82 | 2023-2024 | Sotyktu, Eliquis |
| Lucid Diagnostics INC. | $240.73 | 2025 | |
| Amgen INC. | $193.53 | 2021-2024 | Evenity, Tepezza, Prolia |
| Medtronic, INC. | $186.66 | 2023-2024 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $185.51 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $165.50 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.50 | 2019-2024 | Jardiance |
| Medtronic Minimed, INC. | $137.96 | 2019 | |
| Alexion Pharmaceuticals, INC. | $135.99 | 2024 | Strensiq |
| Genzyme Corporation | $120.76 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.94 | 2023 | |
| Dexcom, INC. | $94.72 | 2021-2024 | Dexcom G6 Transmitter |
| Insulet Corporation | $82.86 | 2021-2024 | Omnipod |
| Kyowa Kirin, INC. | $68.11 | 2023-2024 | Crysvita |
| Lilly USA, LLC | $49.90 | 2023 | Baqsimi, Jardiance, Lyumjev |
| Radius Health, INC. | $49.72 | 2023-2024 | Tymlos |
| Xeris Pharmaceuticals, INC. | $47.01 | 2023 | Recorlev |
| Recordati_rare_diseases_inc. | $46.24 | 2024 | Isturisa, Signifor Lar |
| Mannkind Corporation | $36.90 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $27.69 | 2023 | Crysvita |
| Pfizer INC. | $24.39 | 2022 | |
| Amryt Pharma Holdings LTD | $23.02 | 2023 | |
| Abbvie INC. | $22.16 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Mrkaic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.